Cargando…
EBV-gp350 Confers B-Cell Tropism to Tailored Exosomes and Is a Neo-Antigen in Normal and Malignant B Cells—A New Option for the Treatment of B-CLL
gp350, the major envelope protein of Epstein-Barr-Virus, confers B-cell tropism to the virus by interacting with the B lineage marker CD21. Here we utilize gp350 to generate tailored exosomes with an identical tropism. These exosomes can be used for the targeted co-transfer of functional proteins to...
Autores principales: | Ruiss, Romana, Jochum, Simon, Mocikat, Ralph, Hammerschmidt, Wolfgang, Zeidler, Reinhard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3189918/ https://www.ncbi.nlm.nih.gov/pubmed/22022385 http://dx.doi.org/10.1371/journal.pone.0025294 |
Ejemplares similares
-
The EBV Immunoevasins vIL-10 and BNLF2a Protect Newly Infected B Cells from Immune Recognition and Elimination
por: Jochum, Simon, et al.
Publicado: (2012) -
CAR-T Cells Targeting Epstein-Barr Virus gp350 Validated in a Humanized Mouse Model of EBV Infection and Lymphoproliferative Disease
por: Slabik, Constanze, et al.
Publicado: (2020) -
A chimeric EBV gp350/220-based VLP replicates the virion B-cell attachment mechanism and elicits long-lasting neutralizing antibodies in mice
por: Ogembo, Javier Gordon, et al.
Publicado: (2015) -
Engineering extracellular vesicles as novel treatment options: exploiting herpesviral immunity in CLL
por: Gärtner, Kathrin, et al.
Publicado: (2019) -
Development of an Improved Epstein-Barr Virus (EBV) Neutralizing Antibody Assay to Facilitate Development of a Prophylactic gp350-Subunit EBV Vaccine
por: Liu, Hui, et al.
Publicado: (2020)